DEFA14A: Mural Oncology Acquisition: Equity Award Terms Detailed

Mural Oncology plc details the treatment of equity awards for its proposed acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, for a cash consideration of $2.035 to $2.24 per share.

Summary

• Mural Oncology plc (Mural) is being acquired by XRA 5 Corp. (Sub), a wholly-owned subsidiary of XOMA Royalty Corporation, via a Scheme of Arrangement under Chapter 1 of Part 9 of the Companies Act 2014 (Ireland).
• The acquisition offers Mural shareholders a base cash price of $2.035 per share, calculated based on an estimated closing net cash of approximately $36.2 million.
• An additional cash amount of up to $0.205 per share may be paid if Mural's actual closing net cash exceeds the estimated $36.2 million, capping the total consideration at $2.24 per share.
• All outstanding Mural Options, regardless of vesting status, will be cancelled without consideration as their exercise prices are greater than the maximum Scheme Consideration of $2.24 per share.
• Mural RSU Awards will be automatically cancelled and converted into a cash amount equal to the total number of shares subject to the RSU multiplied by the Scheme Consideration.
• Cash payments for cancelled equity awards will be made through payroll as soon as practicable after completion, but no later than 14 days.
• The Mural Board, advised by Lucid Capital Markets, LLC, considers the treatment of Mural Options and RSU Awards fair and reasonable and has unanimously recommended the acquisition to shareholders.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive for shareholders receiving cash consideration, as the acquisition provides a clear exit. However, it is negative for option holders who will receive no value for their awards. The overall sentiment reflects the expected outcome of an announced acquisition, with some uncertainty regarding the additional cash component.

Positives

• Mural RSU Award holders will receive a cash payment equal to the Scheme Consideration for their awards, providing a clear exit value.
• The acquisition provides a defined cash exit for Mural shareholders at a minimum of $2.035 per share and a potential maximum of $2.24 per share.
• The Mural Board has unanimously recommended the acquisition, indicating their belief it is in the best interest of shareholders.

Negatives

• All outstanding Mural Options will be cancelled without any consideration, as their exercise prices exceed the maximum acquisition price of $2.24 per share.
• There is no certainty that the additional cash amount of up to $0.205 per share will be paid, as it depends on Mural's actual closing net cash exceeding the estimated $36.2 million.
• Equity award holders whose employment terminates prior to completion will forfeit unvested awards and may lose the ability to exercise vested options depending on their agreement terms.

Risks

• Uncertainties exist regarding the timing and completion of the Scheme Meeting and Extraordinary General Meeting (EGM).
• There is a risk that Mural shareholders may not approve the Scheme Meeting Resolution or the Required EGM Resolutions.
• Closing conditions for the acquisition may not be satisfied or waived, including the potential failure to receive sanction of the Scheme by the High Court.
• Ongoing costs to Mural could result in the company's Closing Net Cash not exceeding the Estimated Closing Net Cash, leading to no Additional Price Per Share being paid to shareholders.
• General business risks pertaining to Mural, as described in its most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and XOMA Royalty's business risks, as described in its Form 10-Q and other SEC filings.

Future Outlook

The acquisition is expected to be completed following shareholder approval and sanction by the High Court of Ireland. The payment of an additional cash amount per share is contingent on Mural's actual closing net cash exceeding the estimated $36.2 million, with confirmation expected prior to the High Court hearing.

Management Comments

• The Mural Board, advised by Lucid Capital Markets, LLC, considers the treatment of the Mural Options and Mural RSU Awards described in this communication to be fair and reasonable.
• The Mural Directors have unanimously recommended that Mural Shareholders vote in favour of the Acquisition and the Scheme.

Industry Context

This acquisition represents a consolidation event within the biotechnology or pharmaceutical sector, where smaller companies like Mural Oncology plc are acquired by larger entities or royalty corporations like XOMA Royalty Corporation, often for their assets, pipeline, or intellectual property. Such transactions are common as companies seek to optimize portfolios or provide an exit for shareholders of development-stage firms.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• The acquisition requires sanction by the High Court of Ireland, which is a standard legal proceeding for a Scheme of Arrangement.

Stakeholder Impact

• Shareholders: Will receive a cash consideration of $2.035 to $2.24 per share, providing a liquidity event.
• Mural RSU Award Holders: Will receive cash payments for their awards based on the Scheme Consideration.
• Mural Option Holders: Will have their options cancelled without consideration due to exercise prices exceeding the acquisition price.
• Employees: Those with unvested equity awards whose employment terminates prior to completion will forfeit those awards. Continued employment post-acquisition is not detailed but implied by the transition to a subsidiary.

Next Steps

• Mural Shareholders will vote on the Scheme Meeting Resolution and EGM Resolutions to approve the Acquisition and Scheme.
• The Irish High Court will hold a hearing for the application to sanction the Scheme.
• Confirmation of the Additional Price Per Share will be communicated to Mural Shareholders by announcement prior to the High Court hearing.
• Completion of the Acquisition, upon satisfaction or waiver of all conditions.

Key Dates

Recommendation

For existing shareholders, the recommendation is to hold their shares to receive the cash consideration from the acquisition, which has been unanimously recommended by the Mural Board and is proceeding as detailed. For option holders, the recommendation is effectively 'do nothing' as they will receive no consideration. For RSU holders, they will automatically receive cash. For new investors, the company is being acquired, so there is no long-term investment thesis for Mural Oncology plc itself, making a 'hold' for existing shareholders the most appropriate general recommendation for the stock in the context of this filing.

Keywords

Mural Oncology, XOMA Royalty, Acquisition, Scheme of Arrangement, Equity Awards, Stock Options, RSU Awards, Cash Consideration, Merger, Biotechnology, Pharmaceutical